Orlistat is too carcinogenic

Orlistat (Orlistat) is a prescription drug used to help with weight loss and obesity management. It reduces the intake of calories by blocking the absorption of fat in the digestive tract. While orlistat can cause some uncomfortable side effects in some people, such as diarrhea, greasy stools, and digestive problems, these are usually temporary and manageable.

Carcinogenicity studies in rats and mice did not demonstrate the carcinogenic potential of orlistat at doses up to 1000 mg/kg/day and 1500 mg/kg/day, respectively. For mice and rats, these doses were 38 and 46 times the human daily dose calculated based on the area of u200bu200bthe concentration-time curve for total drug-related substances. Orlistat has no detectable mutagenic or genotoxic activity as determined by the Ames assay, mammalian forward mutation assay (V79/HPRT), in vitro peripheral human lymphocyte lysis assay, unprogrammed DNA synthesis assay (UDS) in cultured rat hepatocytes, and in vivo mouse micronucleus assay. In a fertility and reproduction study, orlistat had no observable side effects when administered to rats at a dose of 400 mg/kg/day.

The original drug of Orlistat has been marketed in China, but it has not yet entered the scope of medical insurance. There are also domestically produced drugs developed by other pharmaceutical companies on the market. The price of each box may be around tens of RMB, which is cheap. The price of the Indian version of Orlistat listed overseas is 120mg*84 capsules per box, which may be around a few hundred yuan (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same, but the manufacturers are different, and patients can choose by themselves.